PRESS RELEASE published on 02/15/2024 at 12:30, 7 months 13 days ago NanoViricides Has Filed its Quarterly Report - NV-387 Clinical Trial Healthy Subjects Part Successfully Completed, COVID Patient Treatment on the Horizon NanoViricides, Inc. files Quarterly Report on Form 10-Q with SEC, reports financial status and cash balance of $5.31 Million. Company makes strategic moves to improve liquidity and prepares for Phase II clinical trials Quarterly Report Clinical Trials Form 10-Q NanoViricides Inc. Financial Status
PRESS RELEASE published on 02/01/2024 at 12:20, 7 months 27 days ago Clinical Trial Demonstration of Safety and Tolerability of NV-CoV-2 Has Implications Beyond COVID Treatment, Explains NanoViricides - NV-387 Could be As Revolutionary as Antibiotics NanoViricides, Inc. reports on the strong safety and tolerability of NV-CoV-2 oral drug products, showcasing their potential for long-term success and broad-spectrum antiviral capabilities, including against RSV and Smallpox-like viruses NV-387 NanoViricides Inc Antiviral Drugs Nanoviricides Platform COVID Therapeutics
PRESS RELEASE published on 01/29/2024 at 12:30, 7 months 30 days ago Safety in Multiple-Ascending-Dose Healthy Subjects Clinical Trial Part Successfully Established for the NanoViricides Ultra-Broad-Spectrum Antiviral Drug NV-CoV-2 with No Adverse Events Found NanoViricides, Inc. successfully completes Phase 1a/1b Clinical Trial of NV-CoV-2, reporting excellent safety and broad-spectrum antiviral activity of NV-387 against various respiratory viruses including Coronaviruses and RSV NV-387 NanoViricides Inc NV-CoV-2 Phase 1a/1b Clinical Trial Antiviral Therapy
PRESS RELEASE published on 01/04/2024 at 12:30, 8 months 24 days ago NanoViricides to Present at the Biotech Showcase in San Fransisco NanoViricides, Inc., a leader in antiviral therapies based on nanomedicines technology, is set to present at the Biotech Showcase™ 2024 in San Francisco. The presentation will include an update on the successful Phase 1 clinical trials of NV-CoV-2 Oral Syrup and Oral Gummies, which contain the novel antiviral nanomachine NV-387. The company's President will discuss how NV-387 addresses the unmet need for a broad-spectrum antiviral drug as well as its potential across multiple virus families. With its wide spectrum of antiviral activity, NV-387 has the potential to revolutionize antiviral treatment, much like antibiotics did for bacterial infections. NanoViricides Antiviral Therapies NV-387 Biotech Showcase 2024 Broad-spectrum Antiviral Drug
PRESS RELEASE published on 11/28/2023 at 12:40, 10 months ago The Phase 1a/1b Human Clinical Trial of NV-CoV-2, the Company’s Broad-Spectrum Antiviral Drug, Has Successfully Completed the First Part (Phase 1a), Reports NanoViricides
PRESS RELEASE published on 11/15/2023 at 12:45, 10 months 13 days ago NanoViricides Has Filed its Quarterly Report - NV-387 Broad-Spectrum Antiviral in Clinical Trials Has Additional Applications
PRESS RELEASE published on 11/14/2023 at 12:45, 10 months 14 days ago Broad-Spectrum Antiviral NV-387 (NV-CoV-2) in Phase 1a/1b Clinical Trial is Highly Effective in an Animal Model for MPox and Smallpox Drug Development
PRESS RELEASE published on 10/16/2023 at 12:45, 11 months 12 days ago NanoViricides, Inc. Has Filed its Annual Report: Broad-spectrum Antiviral NV-387 (NV-CoV-2) in Phase 1a/1b Clinical Trial is Highly Active Against Coronaviruses as well as RSV
PRESS RELEASE published on 10/12/2023 at 12:45, 11 months 16 days ago NanoViricides, Inc. to Present at the Partnership Opportunities in Drug Delivery Conference in Boston on October 16, 2023 at 6:07pm ET
PRESS RELEASE published on 08/21/2023 at 12:45, 1 year 1 month ago The Phase 1a/1b Human Clinical Trial of NV-CoV-2, the Company’s Broad-Spectrum Antiviral Drug, is Progressing Successfully, Reports NanoViricides
Published on 09/28/2024 at 02:06, 18 hours 54 minutes ago Global Education Communities Corp. Reports Second Tranche Closing of Non-Brokered Private Placement
Published on 09/28/2024 at 02:00, 19 hours ago bettermoo(d)’s Moodrink(TM) Featured in Banners of Well-Known Canadian Retailers
Published on 09/28/2024 at 00:10, 20 hours 50 minutes ago LQWD Technologies Announces Non-Brokered Private Placement Update
Published on 09/28/2024 at 14:01, 6 hours 59 minutes ago Turkiye Garanti Bankasi A.S.: Explanation on Subordinated Debt Securities to Qualified Investors
Published on 09/27/2024 at 22:30, 22 hours 30 minutes ago DREAM Pivotal Study Data Presented at the International Surgical Sleep Society 2024 Educational Update
Published on 09/27/2024 at 21:56, 23 hours 3 minutes ago EQS-Adhoc: FDA grants approval for Stelara® Biosimilar FYB202/OtulfiTM (ustekinumab-aauz)
Published on 09/27/2024 at 18:50, 1 day 2 hours ago PETROFAC ANNOUNCES IN-PRINCIPLE AGREEMENT ON FINANCIAL RESTRUCTURE
Published on 09/27/2024 at 18:40, 1 day 2 hours ago Fuller, Smith & Turner PLC: Transaction in own shares
Published on 09/27/2024 at 17:45, 1 day 3 hours ago NFL BIOSCIENCES: 2024 FIRST-HALF BUSINESS AND EARNINGS UPDATE
Published on 09/26/2024 at 18:00, 2 days 3 hours ago GUILLEMOT CORPORATION: Availability of the interim financial report to June 30, 2024
Published on 09/26/2024 at 18:00, 2 days 3 hours ago GUILLEMOT CORPORATION: 2024 CONSOLIDATED INTERIM RESULTS
Published on 09/26/2024 at 17:47, 2 days 3 hours ago imerys-26-September-2024-information-share-capital-and-voting-rights-as-of-31-August-2024